Kymera Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio55.3517.9829.2544.7580.75
P/B Ratio3.123.582.797.099.68
Price/Tangible Book3.123.582.797.099.68
Price/FCF34.77
Price/OCF31.18
Enterprise Value Ratios
EV/Revenue37.8713.4716.8836.6167.15
EV/FCF28.92
Profitability & Returns
Return on Equity (ROE)-0.36%-0.33%-0.33%-0.27%-0.29%
Return on Assets (ROA)-0.21%-0.18%-0.17%-0.12%-0.10%
Return on Capital Employed (ROCE)-0.28%-0.34%-0.30%-0.20%-0.12%
Leverage & Solvency Ratios
Debt/Equity0.100.210.040.040.06
Debt/FCF0.23
Liquidity Ratios
Current Ratio7.534.735.884.882.73
Quick Ratio7.234.595.744.782.69
Efficiency Ratios
Asset Turnover0.060.130.080.130.11
Yield & Distribution Ratios
Earnings Yield-0.09%-0.10%-0.11%-0.03%-0.02%
FCF Yield-0.08%-0.10%-0.11%-0.04%0.03%
Buyback Yield-0.29%-0.08%-0.12%-1.77%-9.21%